Discover what healthcare professionals (HCPs) think about pharmaceutical products and their manufacturers, as it happens, through CREATION.co’s tracking updates. How are HCPs responding to drug launch news? How are HCPs talking about or engaging with the Top 50 pharma companies on social media? Each week CREATION.co’s tracking updates bring you the latest insights from the conversation of HCPs across the globe discussing these topics and more.
February’s Top 50 Pharmaceutical Companies mentioned by HCPs on Twitter
| April Rank | March Rank | Company Name | Total Mentions | Account Mentions | Account Retweets |
|---|---|---|---|---|---|
| 1 | 1 | AstraZeneca | 43,405 | 1,587 | 15 |
| 2 | 2 | Pfizer | 36,725 | 2,596 | 196 |
| 3 | 3 | Johnson & Johnson | 14,895 | 1,392 | 161 |
| 4 | 4 | GSK | 889 | 310 | 46 |
| 5 | 6 | Merck & Co | 545 | 456 | 184 |
| 6 | 10 | Abbott | 474 | 433 | 22 |
| 7 | 9 | Sanofi | 493 | 263 | 88 |
| 8 | 8 | Roche | 469 | 145 | 33 |
| 9 | 7 | Novartis | 341 | 233 | 45 |
| 10 | 5 | Lilly | 258 | 188 | 64 |
| 11 | 13 | Gilead | 328 | 110 | 11 |
| 12 | 12 | Bayer | 299 | 101 | 14 |
| 13 | 11 | Novo Nordisk | 189 | 150 | 30 |
| 14 | 17 | Regeneron | 230 | 68 | 2 |
| 15 | 22 | AbbVie | 146 | 128 | 10 |
| 16 | 14 | BMS | 131 | 113 | 12 |
| 17 | 18 | Boehringer | 115 | 106 | 28 |
| 18 | 25 | Biogen | 124 | 71 | 3 |
| 19 | 21 | Amgen | 105 | 65 | 24 |
| 20 | 15 | Otsuka | 185 | 3 | 2 |
| 21 | 19 | Fresenius | 87 | 69 | 32 |
| 22 | 35 | Ipsen | 62 | 60 | 31 |
| 23 | 23 | UCB | 49 | 46 | 33 |
| 24 | 31 | Merck KGaA | 54 | 52 | 7 |
| 25 | 16 | Takeda | 60 | 45 | 7 |
| 26 | 20 | Servier | 64 | 32 | 3 |
| 27 | 33 | Menarini | 36 | 34 | 8 |
| 28 | 30 | Teva | 35 | 27 | 15 |
| 29 | 26 | Chugai | 49 | 5 | 2 |
| 30 | 28 | CSL | 23 | 20 | 8 |
| 31 | 37 | Alexion | 29 | 20 | 0 |
| 32 | 39 | Vertex | 19 | 18 | 0 |
| 33 | 24 | Mylan | 34 | 2 | 0 |
| 34 | 32 | Allergan | 26 | 3 | 0 |
| 35 | 29 | Astellas | 17 | 7 | 1 |
| 36 | 27 | Daiichi Sankyo | 18 | 3 | 1 |
| 37 | 34 | Eisai | 11 | 9 | 0 |
| 38 | 36 | Bausch | 17 | 2 | 0 |
| 39 | 40 | Sun | 17 | 2 | 0 |
| 40 | 38 | Grifols | 13 | 1 | 0 |
| 41 | 42 | Mitsubishi Tanabe Pharma | 1 | 1 | 0 |
| 42 | 50 | Sumitomo Dainippon | 2 | 0 | 0 |
| 43 | 50 | Endo | 1 | 0 | 0 |
| 50 | 41 | Aurobindo | 0 | 0 | 0 |
| 50 | 50 | Jiangsu Hengrui | 0 | 0 | 0 |
| 50 | 50 | Meiji | 0 | 0 | 0 |
| 50 | 50 | Ono | 0 | 0 | 0 |
| 50 | 50 | Shanghai | 0 | 0 | 0 |
| 50 | 50 | Sino | 0 | 0 | 0 |
| 50 | 50 | Yunnan Baiyao | 0 | 0 | 0 |
February’s insights from HCPs mentioning the Top 50 Pharmaceutical Companies
During the month of February 2021, the five pharmaceutical companies most talked about by healthcare professionals (HCPs) on Twitter remained the same as the previous month. However, GSK surpassed Sanofi and was positioned as the fourth most mentioned pharmaceutical company. The final ranking was Pfizer, AstraZeneca, Johnson and Johnson (J&J), GSK and Sanofi.
HCPs continued to discuss the safety and efficacy of COVID-19 vaccines. Regarding Pfizer’s they referenced a study developed in Israel indicating a significant decrease of COVID-19 infections in the population. When discussing AstraZeneca’s vaccine some HCPs mentioned a decrease in efficacy against the B1351 COVID-19 variant found first in South Africa, while others focused on its protection against serious illness and transmission from COVID-19 – SARSCoV2. Another topic making up a large proportion of HCPs’ mentions was the FDA approval of J&Js vaccine.
The volume of posts from HCPs about top 50 pharma companies decreased when compared to the month of January, primarily due to the volume of posts about Pfizer decreasing by 18%. However, HCP posts mentioning AstraZeneca and J&J increased by 22% and 44% respectively.
1/7 – “The #COVID19 vaccine made by BioNTech and Pfizer has been highly effective at preventing infection in Israel, according to the first real-world data showing that vaccination stops transmission of the virus.”https://t.co/b1dwdWALzO
— Antoine FLAHAULT (@FLAHAULT) February 21, 2021
Very positive news for #COVID19 on the Johnson & Johnson vaccine. Approval from the @US_FDA now very likely on Friday – this is a single dose-vaccine.https://t.co/42U8ZE8LoW
— Anthony Staines (@astaines) February 24, 2021
The most shared links by HCPs, from a variety of sources, revealed key updates about the vaccines, including J&J’s recent FDA approval:
- A study from The New England Journal of Medicine confirming the efficacy of the Pfizer vaccine was the most shared by HCPs. The study gathered data from a mass vaccination campaign in Israel and the findings suggest that risk of illness from COVID-19 declined among Israeli individuals after receiving both doses of the vaccine.
- The FDA review of J&J’s vaccine focusing on its safety and efficacy was the second most shared resource by HCPs.
- In third place, HCPs shared the pre-print SIREN study taking place in the UK. The study was done among healthcare workers and suggests effectiveness against infection of COVID-19.
The volume of COVID-19 conversation in the context of top 50 pharma also decreased, down 19% from January to February, however was a similar proportion of the total conversation in February, 73% compared to 74% in January.
Outside of the COVID-19 conversation, HCPs used social media to discuss treatment for a variety of diseases as well as sharing virtual events sponsored by pharmaceutical companies. For example, an article investigating how the company Eli Lilly has influenced the treatment of diabetes with a low carb diet was shared among HCPs. Additionally, HCP Toby Eyre shared the Haematology Summit organized by Janssen in the UK where he would be answering questions regarding lymphoma.
Roche’s novel anti-TIGIT tiragolumab granted FDA Breakthrough Therapy Designation in combination with Tecentriq for PD-L1-high non-small cell lung cancer https://t.co/xppMzPKwSB via @YahooNews
— Christine Lovly, MD, PhD (@christine_lovly) January 5, 2021
I will be answering your questions at the medically organised @JanssenUK Haematology Summit on Thurs 25 Feb (10-10:45am): 'More questions about lymphoma? Q&A session'.
UK and Ireland HCPs only can register at https://t.co/mFB4QPNhe9— Toby Eyre (@tobyeyre82) February 11, 2021
CREATION.co continues to analyse online HCP conversation on a variety of topics including virtual congress, healthcare changes since the pandemic, product development and therapy area specific insights.
To stay up to date, you can sign up to CREATION.co’s monthly eJournal.
- In February 2021, CREATION Pinpoint® identified 55,284 healthcare professional (HCP) authored tweets from 17,842 individual HCPs mentioning a top-50 pharmaceutical company (according to revenue).
- Data for this research was analysed from the online Twitter conversations of HCPs in all languages mentioning a Top 50 pharmaceutical company between February 1st and February 28th 2021.
- Unless otherwise specified, mentions of a company are not limited to its Twitter account(s).
- In some cases, a tweet may mention more than one company account (eg. @abbottnews and @abbottglobal) – this only counts as one Company Mention and Account Mention.
- Johnson & Johnson was included as a whole, encompassing its pharmaceutical subsidiary, Janssen. In February, 1,395 of these posts mentioned Janssen.
